MAPT and Alzheimer disease: Interestingly, indirect ELISA using the HJ8.7 (anti-tau118-122 AAGHV) antibody [30] revealed significantly higher tau in CDR0 group compared with all AD pathology positive samples (F(3,25) = 3.751, p = 0.0237; CDR0 vs CDR0+: p = 0.0484, CDR0 vs CDR1: p = 0.0005, and CDR0 vs CDR3: p = 0.0002) (S1 Fig) while no difference was found when using the HJ9.3 (anti-tau589-598 GGKVQIINKK) antibody [30] (F(3,25) = 1.004, p = 0.4075; S1 Fig).